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α-1 antitrypsin (AAT) deficiency can exhibit two patho-
logic states: a lung disease that is primarily due to the 
loss of AAT’s antiprotease function, and a liver disease 
resulting from a toxic gain-of-function of the PiZ-AAT 
(Z-AAT) mutant protein. We have developed several 
recombinant adeno-associated virus (rAAV) vectors that 
incorporate microRNA (miRNA) sequences targeting the 
AAT gene while also driving the expression of miRNA-
resistant wild-type AAT-PiM (M-AAT) gene, thus achiev-
ing concomitant Z-AAT knockdown in the liver and 
increased expression of M-AAT. Transgenic mice express-
ing the human PiZ allele treated with dual-function 
rAAV9 vectors showed that serum PiZ was stably and 
persistently reduced by an average of 80%. Treated ani-
mals showed knockdown of Z-AAT in liver and serum 
with concomitant increased serum M-AAT as determined 
by allele-specific enzyme-linked immunosorbent assays 
(ELISAs). In addition, decreased globular accumulation 
of misfolded Z-AAT in hepatocytes and a reduction in 
inflammatory infiltrates in the liver was observed. Results 
from microarray studies demonstrate that endogenous 
miRNAs were minimally affected by this treatment. These 
data suggests that miRNA mediated knockdown does 
not saturate the miRNA pathway as has been seen with 
viral vector expression of short hairpin RNAs (shRNAs). 
This safe dual-therapy approach can be applied to other 
disorders such as amyotrophic lateral sclerosis, Hunting-
ton disease, cerebral ataxia, and optic atrophies.
Received 28 September 2011; accepted 8 December 2011; advance 
online publication 17 January 2012. doi:10.1038/mt.2011.292
IntroductIon
α-1 antitrypsin (AAT) is one of the primary circulating serum 
antiproteases in humans. It inhibits a variety of serine protei-
nases, with neutrophil elastase being one of the most physiologi-
cally important due to its role in lung infections, and inhibits a 
number of metalloproteinases and other proinflammatory and 
proapoptotic molecules. AAT is normally produced within hepa-
tocytes and macrophages, where hepatocyte-derived AAT forms 
the bulk of the physiologic reserve of AAT. Approximately 4% of 
North American and Northern European populations possess at 
least one copy of a mutant allele, known as PI*Z (Z-AAT) which 
results from a single amino acid substitution of lysine for gluta-
mate at position 342. In the homozygous state, this mutation leads 
to severe deficiency of AAT, resulting in a lung disease that is pri-
marily due to the loss of antiprotease function and a liver disease 
(lifetime risk of developing liver disease is as high as 50%.) result-
ing from a toxic gain of function of the Z-AAT mutant protein.1 
Mutant Z-AAT lacks a crucial salt-bridge in a β-sheet region of the 
protein, allowing for the insertion of the reactive loop of a neigh-
boring AAT molecule in between the two β-sheets,2 resulting in a 
very stable loop–sheet polymer.3 This polymer accumulates within 
hepatocytes, resulting in serum deficiency due to inefficient secre-
tion. In individuals affected by AAT liver disease, it also triggers 
mitochondrial injury, caspase activation, autophagy and apoptosis 
within the hepatocyte, likely the result of endoplasmic reticulum 
accumulation.4–6 However, the details remain unclear, as does the 
reason for the disparity between those Z-homozygotic individu-
als who develop liver disease and those who do not. Nevertheless, 
there is consensus that molecular therapies for AAT liver disease 
should act by downregulating Z-AAT.
Our group has developed two investigational clinical gene ther-
apy products for gene augmentation of AAT as a potential therapy 
for the lung disease by using the recombinant adeno-associated 
viral vectors (rAAV2-AAT and rAAV1-AAT).7,8 However, because 
a decrease in the expression of Pi*Z mutant protein is required 
to halt or ameliorate the hepatocellular damage, researchers tried 
to downregulate AAT messenger RNA (mRNA). One approach 
was to utilize hammerhead ribozymes designed to cleave AAT 
mRNA at a specific site.9 Another approach, is the application of 
RNA interference (RNAi) to decrease levels of the mutant mRNA 
transcript.10 In our lab, small short hairpin RNAs (shRNAs) were 
designed to downregulate endogenous AAT within hepatocytes.11 
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Although this strategy proved effective, the optimal approach 
would be one that knocks down PiZ protein while at the same 
time increasing M-AAT protein. Our initial shRNA experiments 
relied on polymerase III U6-based promoters and did not show 
any liver-associated toxicity although we only followed mice for 
4 weeks post shRNA delivery. However other groups have impli-
cated AAV-mediated shRNA delivery with toxic side-effects, in 
one instance shRNA delivery to liver was associated with toxic-
ity only when shRNAs greater that 19 base pairs in length.12,13 In 
addition to controlling for the length of the shRNA it has also 
been shown that toxicity can be avoided employing RNAi with 
microRNAs (miRNAs) instead of shRNAs.14 Despite this, recently 
bicistronic AAV vectors expressing shRNAs against PiZ AAT 
and a codon-optimized AAT gene have been evaluated in mice. 
However the study had several limitations, mainly serum AAT 
protein detection showing effective knockdown of mutant and 
concomitant augmentation of normal AAT was not clearly dem-
onstrated and was only convincingly shown by mRNA transcript 
analysis. In addition, these studies were limited to a duration of 2 
weeks post AAV delivery and did not address long-term sustained 
knockdown and augmentation therapy or previous finding with 
shRNA-mediated liver toxicity.15
We have therefore examined a number of approaches for 
long-term expression of therapeutic miRNAs using the rAAV 
platform. miRNAs are single-stranded RNA molecules of about 
21–23 nucleotides in length, that are able to regulate gene expres-
sion. These regulatory RNA molecules, which can be found in the 
intronic regions of protein coding genes of mammals, from stem 
loop structures that are recognized by a protein complex known 
as the microprocessor. This complex, consisting of the nuclease 
Drosha and the RNA-binding domain DGCR8, recognizes the 
pri-miRNAs stem loops and cleaves them out.16 The resulting pre-
miRNAs are then exported out of the nucleus into the cytoplasm 
where they are processed by Dicer resulting in a mature 21–23 
nucleotide miRNA that then enters the RNA-induced silenc-
ing complex thereby silencing its mRNA target.17 We have taken 
advantage of this pathway by altering the sequence of miR-155 to 
create artificial miRNAs that target the human AAT gene.
Although it is feasible to simultaneously direct silencing 
agents to the liver to decrease Z-AAT expression and direct gene 
augmentation to other sites, the liver is also the optimal target tis-
sue for augmentation. Thus, here we demonstrate a miRNA-based 
approach to stably downregulate Z-AAT within hepatocytes that 
allows for simultaneous M-AAT gene augmentation from the 
same rAAV gene delivery vector without serious perturbation of 
the overall hepatic miRNA profile.
results
Artificial mirnAs efficiently downregulate AAt in vitro
Previously we had demonstrated efficient Z-AAT knockdown 
in vivo and in vitro using shRNAs expressed from a polymerase 
III U6 promoter with rAAV8.11 To determine an alternative and 
potentially safer approach with polymerase II-driven miRNA 
expression, we cloned three distinct miRNAs targeting the human 
AAT gene within the intron of a hybrid chicken β-actin (CB) pro-
moter driving green fluorescent protein (GFP) expression (Table 1 
and Figure 1a,b). The artificial miRNAs are based on the miR-155 
backbone and have been designed to specifically target the coding 
sequence of human AAT gene. We compared in vitro the previ-
ously used U6-driven shRNAs and the polymerase II-driven miR-
NAs in cell lines expressing the human Pi*Z AAT gene. By 48 and 
72 hours of incubation, we noted a comparable ~35% reduction 
in secreted AAT protein for both constructs, as compared to GFP 
controls (Figure 1a). A similar reduction was observed in intrac-
ellular AAT protein levels assayed from the cell pellets at 72 hours 
(Figure 1b).
rAAV9 expressed mirnAs mediate efficient 
AAt knockdown in vivo
On the basis of our in vitro findings, we packaged the construct 
with the three intronic miRNA sequences (intronCB-3XmiR) 
along with three other constructs containing the individual 
miRNAs directed against the Z-AAT in rAAV and tested in vivo 
in the PiZ-transgenic mice. These transgenic mice were previ-
ously generated by introducing the 14.4 kb human PiZ AAT 
gene which included 2.0 and 2.3 kb of the 5′ and 3′ untranslated 
regions into the germline of mice. The resulting mice are thus 
able to express human AAT in a tissue-specific manner with 
normal regulation of gene transcription.18 In humans, normal 
serum AAT levels range between 104–276 mg/dl and in homozy-
gous PiZ patients the median value is around 28 mg/dl, our PiZ 
mouse colony has higher circulating levels of Z-AAT at around 
90 mg/dl, probably owing to the fact that transgenic mice usu-
ally have more than two copies of the transgene inserted into the 
genome. Regardless, these mice model the human liver pathol-
ogy quite faithfully. Five groups of 5-week-old mice received: 
rAAV9-CB-GFP, rAAV9-intronCB-3xmiR-GFP or vector with 
either one of the individual miRNA via a tail vein injection with 
5.0 × 1011 virus particles (vps) of rAAV9. Mice were bled weekly 
for 5 weeks to check for circulating Z-AAT and were killed on 
day 35 after rAAV delivery. Serum PiZ levels were then ana-
lyzed for each time point and graphed as percent change from 
the control GFP injected mice at the respective time point. As 
table 1 Artificial mirnA sequences
AAt gene start site mir-155 5′ flanking sequence targeting stem loop mir-155 3′ flanking sequence
910 CCTGGAGGCTTGCTGAAGGCT 
GTATGCTG
TAAGCTGGCAGACCTTCTGTCGTTTTGGC 
CACTGACTGACGACAGAAGCTGCCAGCTTA
CAGGACACAAGGCCTGTTACTAGCA 
CTCACATGGAACAAATGGCCTCTAGA
914 CCTGGAGGCTTGCTGAAGGCT 
GTATGCTG
AATGTAAGCTGGCAGACCTTCGTTTTGGC 
CACTGACTGACGAAGGTCTCAGCTTACATT
CAGGACACAAGGCCTGTTACTAGCA 
CTCACATGGAACAAATGGCCTCTAGA
943 CCTGGAGGCTTGCTGAAGGCT 
GTATGCTG
ATAGGTTCCAGTAATGGACAGGTTTTGGC 
CACTGACTGACCTGTCCATCTGGAACCTA
CAGGACACAAGGCCTGTTACTAGCA 
CTCACATGGAACAAATGGCCTCTAGA
Abbrevations: AAT, α-1 antitrypsin; miRNA, microRNA.
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shown on Figure 1c mice receiving intronCB-3XmiRNAs had 
on average a sustained 50–60% decrease in serum AAT, while 
mice receiving the single intronic miRNAs had on average 
a knockdown of 30% as compared to mice receiving the GFP 
control vector.
To further evaluate the effect of miRNA-mediated Z-AAT 
knockdown we tested the livers of these mice 5 weeks after 
rAAV delivery for abundance of intracellular Z-AAT. We saw 
a marked decrease in AAT positive staining as indicated by the 
brown immunostaining in the livers of mice in the rAAV9-
intronCB-3XmiR-GFP treated group (Figure 2a,b). An alter-
native staining method to visualize the aggregation of Z-AAT 
which is used clinically is by performing a periodic acid Schiff 
(PAS) stain after a diastase digestion of the tissue. The diastase 
digestion breaks down the glycogen leaving behind the Z-AAT 
protein accumulation as positive staining. With this method we 
also noted a decrease in intracellular AAT globules as deter-
mined by diastase-resistant PAS (PASD) positive staining 
(Figure 2c–f). Quantitative image analysis of whole liver sec-
tions with an algorithm designed to detect PASD-positive pix-
els also revealed about a 40% reduction in Z-AAT protein in 
the intronCB-3XmiR-GFP group (Figure 2g). The reduction in 
both PASD and hAAT staining was accompanied by a reduc-
tion in inflammatory foci, this reduction was only evident in 
the intronCB-3XmiR-GFP group but not in the control GFP 
group (Figure 2c,d, black arrows). This suggests that the reduc-
tion in hAAT accumulation in the PiZ mice livers may alleviate 
inflammation.
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Figure 1 MicrornA mediated knockdown of human AAt. HEK-293 cells were contrasfected with human Z-AAT plasmid and either a plasmid 
expressing three anti-AAT shRNAs from a U6 promoter or a plasmid expressing three anti-AAT miRNA from a hybrid chicken β-actin promoter. (a) 
Culture media was harvested at 24, 48, and 72 hours and was analyzed for the AAT concentration by ELISA. (b) At 72 hours cells were harvested and 
lysed for AAT concentration by ELISA. *≤0.05 as determined by a two-way unpaired Student’s t-test. (c) Transgenic mice expressing the human PiZ 
allele were injected with 5 × 1011 virus particles of a rAAV9 control GFP vector or rAAV9 expressing miRNAs against AAT under the control of the hybrid 
chicken β-actin promoter via the tail vein. Serums from each cohort were collected on a weekly basis and were used to assess Z-AAT concentration 
by ELISA. Serum Z-AAT levels at each timepoint are expressed as a percent knockdown as compared to the rAAV9-GFP cohort. Data are expressed as 
group means ± SEM (n = 6). Statistical significance was set at *≤0.05 as determined by a two-way ANOVA comparing each treatment group to the 
control rAAV-GFP group. AAT, α-1 antitrypsin; ANOVA, analysis of variance; CMV, cytomegalovirus; ELISA, enzyme-linked immunosorbent assay; GFP, 
green fluorescent protein; miRNA, microRNA; rAAV, recombinant adeno-associated virus; shRNA, short hairpin RNA.
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onset and degree of knockdown depend on mirnA 
location within the expression cassette
We next determined whether the location of the miRNAs within 
the expression cassette had any effect on their efficiency. We inves-
tigated whether cloning the three miRNAs between the 3′ end 
of the GFP gene and the polyA tail changed the kinetics of AAT 
knockdown and whether expressing the miRNAs from both loca-
tions (intron and polyA) which should double the amount of miR-
NAs being produced would in turn lead to a further enhancement 
of AAT knockdown. As in the previous experiments, Z-AAT trans-
genic mice received 5 × 1011 vps of rAAV9 vectors expressing the 
miRNAs either from the intron (intronCB-3XmiR), polyA region 
(PolyA-3XmiR) or at both locations at once (Double-6XmiR) 
(Figure 3a). By 4 weeks the PolyA-3XmiR and Double-6XmiR 
were more effective than the intronCB-3XmiR vector at decreasing 
serum Z-AAT levels by 85–70%, or in some cases with the Double-
6XmiR vector by up to 95% (Figure 3a). Real-time quantitative 
reverse transcriptase-PCR (RT-PCR) analysis of liver tissue from 
these mice was performed to measure each of the three artificial 
vector derived miRs (910, 914, and 943). Both the PolyA-3XmiR 
and Double-6XmiR vectors produced about twice as many copies 
of each of the miRs than the intronCB-3XmiR (Figure 3b).
Having achieved a short-term physiologically significant 
knockdown of more than 50% of Z-AAT serum protein levels, we 
determined whether this knockdown could be sustained for a lon-
ger period of time. The three vector constructs were delivered via 
the tail vein at a slightly higher titer of 1.0 × 1012 vps/mouse and 
serum Z-AAT was monitored weekly for 3 months. The onset of 
the effect of the three vector varied, with the Double-6XmiR vector 
achieving 90% knockdown 2 weeks after delivery, the PolyA-3XmiR 
reaching 90% by the third week, while the intronCB-3XmiR vector 
resulted in 50–65% knockdown for the first 7 weeks (Figure 4a, 
Supplementary Figure S1). In order to monitor if there was any 
liver toxicity associated with rAAV9 delivery or miRNA expres-
sion, we assessed serum alanine and aspartate aminotransferase 
concentrations 2 weeks after rAAV9 delivery. As observed in the 
(Supplementary Figure S2) rAAV9 delivery was not associated 
with increases in either alanine aminotransferase or aspartate 
aminotransferase levels, in fact the Double-6XmiR group had a 
significant reduction in alanine aminotransferase and aspartate 
aminotransferase serum concentrations and trends in the same 
direction were seen with the two other groups expressing anti-
AAT miRs (Supplementary Figure S1). Although Z-AAT serum 
concentration rose slightly in animals in the Double-6XmiR and 
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Figure 2 liver histology for PiZ-transgenic mice 5 weeks post-rAAV9 delivery. Livers from mice receiving rAAV9 vectors with miRNAs and GFP 
controls were formalin-fixed and stained for AAT, or with a PAS-D assay. Mouse liver sections stained using an antihuman AAT antibody from a mouse 
treated with (a) i intronCB-3xmiR-GFP or (b) GFP controls. Mouse liver sections stained with diastase-resistant periodic acid Schiff assay from (c,d) 
GFP controls, black arrows indicate foci of lymphocyte infiltrates or (e,f) intronCB-3xmiR-GFP. (g) Quantitative pixel image analysis of whole liver 
sections for PASD-positive globules comparing pixel counts of GFP controls (n = 7) to intronCB-3xmiR-GFP (n = 7) *≤0.05 as determined by a two-
way unpaired Student’s t-test. AAT, α-1 antitrypsin; CB, chicken β-actin; GFP, green fluorescent protein; miRNA, microRNA; PASD, diastase-resistant 
periodic acid Schiff; rAAV, recombinant adeno-associated virus.
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PolyA-3XmiR groups between week 7 and 13, all three vector 
groups showed stabilized values of serum Z-AAT at a sustained 
knockdown of 75% for the remainder of the study (Figure 4a). 
Further analysis of liver homogenates to determine whether this 
reduction was in the monomer or polymer pools of Z-AAT was 
performed on all groups. This modified western blot separates 
the monomer and polymer Z-AAT fractions under nondenatur-
ing conditions after which they are denatured and quantitatively 
assessed by immunoblotting. As shown in Figure 4b the reduc-
tion in the monomer pool 3 months after miRNA is evident in 
all the groups, densitometric analysis of the bands shows highly 
significant differences in the PolyA-3XmiR and Double-6XmiR as 
compared to mice treated with a GFP vector control(Figure 4c). 
Polymer pool analysis revealed that there was no reduction in the 
Z-AAT polymers fraction even after 90 days (Figure 4d).
In vitro delivery of mirnAs against Z-AAt and gene 
correction with M-AAt in a single vector
On the basis of the success of long-term sustained knockdown of 
Z-AAT, we studied the possibility of creating a dual-function vec-
tor that would simultaneously augment protein levels of the wild-
type M-AAT protein, thereby addressing both liver disease caused 
by the toxic gain-of-function of Z-AAT polymers and the loss-of-
function caused by the absence of circulating M-AAT. To achieve 
this, we replaced the GFP gene in the vector with a wild-type AAT 
gene that had silent base pair changes at the miRNAs’ target sites, 
thus making it resistant to the miRNA-mediated knockdown. 
HEK-293 cells were cotransfected with two plasmids, one of the 
plasmids expressed Z-AAT and the other one contained either the 
Double-6XmiR-GFP, Double-6XmiR-AAT (containing the miRNA-
resistant AAT gene) or a phosphate-buffered saline (PBS) control. 
The transfected cells were incubated for 72 hours and RNA was 
harvested from cell pellets for a quantitative RT-PCR analysis 
of Z-AAT and M-AAT transcripts. Analysis of Z-AAT mRNA 
revealed that both Double-6XmiR-GFP and Double-6XmiR-
AAT produced a significant knockdown (up to 37 times higher) 
in number of Z-AAT mRNA copies as compared to the mock 
transfected cells (Supplementary Figure S3a). Furthermore, 
quantitative RT-PCR for wild-type M-AAT transcripts from the 
same RNA pool revealed that the Double-6XmiR-AAT construct 
expressed M-AAT at values more than 100 times higher than 
the values observed in control transfected cells (Supplementary 
Figure S3b).
In vivo delivery of dual-function vectors
We next used both of these miRNA configurations to test dual-
function vectors in vivo. Three cohorts of seven mice each were 
given 1.0 × 1012 vp with either a GFP control, Double-6XmiR-
CB-AAT or a PolyA-3XmiR-CB-AAT rAAV9 vectors. Serum was 
harvested from the mice on a weekly basis for 13 weeks and was 
analyzed for Z-AAT serum concentrations with a PiZ specific 
ELISA and for M-AAT concentrations with an ELISA detecting 
the cMYC tag on the M-AAT complementary DNA. Changes 
in serum Z-AAT were comparable to those in previous experi-
ments, with a sustained knockdown around 75–85% for both 
vectors (Figure 5a, bottom panel). A more rapid knockdown was 
seen with the Double-6XmiR vector but the PolyA-3XmiR vec-
tor achieved similar values by the fourth week. As serum Z-AAT 
decreased a concomitant rise in circulating M-AAT was observed 
in mice receiving the dual-function vectors (Figure 5a, upper 
panel). Although the amount of knockdown for both vectors was 
similar for 4 weeks after delivery, the production of M-AAT was 
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Figure 3 In vivo optimization of anti-AAt mirnA delivery within rAAV9 vectors. (a) Transgenic mice expressing the human PiZ allele were 
injected with 5 × 1011 virus particles or rAAV9 expressing miRNAs against AAT under the control of the hybrid chicken β-actin promoter via the tail 
vein. Serums from each cohort were collected on a weekly basis and were used to assess Z-AAT concentration by ELISA. (b) Quantitative RT-PCR for 
artificial miRNA was quantified from total RNA obtained from mouse livers. RT-PCR was used to assay for the presence of the three artificial anti-AAT 
miRNAs from mice receiving rAAV9-miRNA vectors. *≤0.05 as determined by a two-way unpaired Student’s t-test. AAT, α-1 antitrypsin; CMV, cyto-
megalovirus; ELISA, enzyme-linked immunosorbent assay; GFP, green fluorescent protein; miRNA, microRNA; rAAV, recombinant adeno-associated 
virus; RT-PCR, reverse transcriptase-PCR.
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significantly different. The PolyA-3XmiR-CB-AAT vector pro-
duced 8–10 times more M-AAT than did the Double-6XmiR-CB-
AAT vector. Liver RNA was extracted from these mice at the end 
of the study to quantify the mRNA levels of Z-AAT and M-AAT. 
As expected there was a precipitous decrease in Z-AAT mRNA 
in both cohorts of mice receiving vectors with miRNAs as com-
pared to mice receiving a rAAV9-CB-GFP control. Quantitative 
RT-PCR for M-AAT was also performed to verify production of 
M-AAT at the RNA level and to determine if the difference in 
M-AAT production between dual-function vectors was related 
to mRNA transcription. Despite the clear difference in M-AAT 
serum protein, there was no statistically significant difference in 
the M-AAT mRNA between the two groups (Figure 5c). This sug-
gests that mRNA translation of M-AAT but not level of transcrip-
tion may be affected in the Double-6XmiR-CB-AAT group.
Analysis of global liver mirnA profiles after delivery 
of artificial mirnAs with rAAV9
We performed a microarray analysis of endogenous mouse miR-
NAs from liver tissue for six groups of mice with five mice per group 
on 30 separate microfluidic chips using samples obtained from the 
long-term Z-AAT knockdown experiments (Figure 6), along with 
five untreated Z-AAT transgenic mice and five C57/BL6 mice. To 
determine baseline differences imparted by the human Z-AAT gene 
in mice, an initial comparison between livers tissue from untreated 
PiZ mice and wild-type C57BL6 mice was performed. There were 
only four statistically significant differences among these mice with 
only miR-1 having a log2 ratio greater than 2, being upregulated in PiZ 
mice (Figure 6a and Table 2). Having established copies miR-1 has 
the most significant difference imparted by the expression of human 
Z-AAT in the transgenic mice, we compared the effects of transduc-
tion on liver miRNA profiles caused by rAAV9-CB-GFP, rAAV9-
Double-6XmiR-CB-GFP, rAAV9-PolyA-3XmiR-CB-GFP, and 
rAAV9-intronCB-3XmiR-CB-GFP liver transduction. The expression 
of our artificial vector derived miRNAs had minimal impact on global 
miRNA profiles (see Figure 6b–d). In general, statistically significant 
differences between untreated PiZ mice and rAAV9 treated mice were 
confined to 2–6 differentially expressed miRNAs depending on the 
rAAV9 vector group. Of these differentially expressed miRNAs, the 
one with the largest change was miR-1, which was downregulated to 
the baseline values observed in the C57Bl6. This correction of miR-1 
upregulation in PiZ mice was observed in all groups including the 
mice receiving only rAAV9-GFP, and thus it seems to be dependent 
on rAAV9 and not on artificial miRNA delivery.
dIscussIon
The results presented in this study describe the initial proof-of-con-
cept and optimization of a combinatorial therapeutic approach for 
the treatment of both liver and lung disease present in patients with 
AAT deficiency. This therapeutic approach is based on a single, dual-
function AAV vector that delivers both miRNAs targeting AAT for 
clearance of mutant mRNA and a miRNA-resistant AAT comple-
mentary DNA for augmentation of wild-type protein. The data clearly 
supports this approach as the biological activities of the miRNAs are 
demonstrated both by cell culture experiments and more importantly 
in vivo after numerous experiments with tail vein delivery of rAAV9-
pseudotyped vectors. With the most effective configuration of the 
miRNAs, we consistently achieved a long-term knockdown of circu-
lating serum Z-AAT in a range of 50–95%. Furthermore when the 
dual-function vectors were used, this knockdown was accompanied 
by equally sustained expression and secretion of wild-type M-AAT.
The optimization of this approach follows our previous study 
demonstrating efficient knockdown of mutant Z-AAT protein in 
PiZ-transgenic mice using a rAAV8 vector expressing U6-driven 
shRNAs.11 Our in vivo experiments show a significant decrease in 
Z-AAT after administration of the rAAV9-intronCB-3xmiR-GFP 
vector (Figure 1c). Importantly these experiments highlight the 
additive effect that was obtained by using three anti-AAT miRNAs 
with different target sequences as none of the vectors with a single 
Figure 4 long-term in vivo silencing of human AAt by rAAV9 
expressed mirnAs. Transgenic mice expressing the human PiZ allele 
were injected with 1 × 1012 virus particles or rAAV9 expressing miRNAs 
against AAT under the control of the hybrid chicken β-actin promoter via 
the tail vein. (a) Serums from each cohort were collected on a weekly basis 
and were used to assess Z-AAT concentration by ELISA. Hepatocytes PiZ 
monomer versus polymer densitometry analysis at 90 days post-rAAV9 
delivery. (b) Immunoblot for AAT after the monomer and polymer sepa-
ration protocol from liver lysates of mice. The 52 kDa Z-AAT was from liv-
ers was processed and separated in into a monomer and polymer pool. 
(c) Densitometric analysis for the monomer and (d) polymer pools was 
performed using Image J software. Statistical significance was considered 
when *P ≤ 0.05 as determined by a two-way unpaired Student’s t-test. 
AAT, α-1 antitrypsin; CB-GFP, chicken β-actin–green fluorescent protein; 
ELISA, enzyme-linked immunosorbent assay; miRNA, microRNA; rAAV, 
recombinant adeno-associated virus.
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miRNA achieved the level of knockdown seen when they were 
delivered in combination (Figure 1c). The other biological effect 
aside from Z-AAT serum reduction that was observed included a 
significant and widespread decrease in the accumulation of Z-AAT 
within the hepatocytes and a reduction of the inflammatory lym-
phocyte foci within the liver (Figure 2). Endoplasmic reticulum 
accumulation of Z-AAT protein results in inflammation which 
overtime can lead to liver fibrosis and eventually to a failing cir-
rhotic liver.4–6 Thus the reduction in inflammatory infiltrates as a 
result of the reduced burden of newly synthesized Z-AAT protein 
is important as it may halt the progression of liver disease and 
fibrotic tissue remodeling as a consequence of inflammation.
Further refinement of the anti-AAT miRNA efficacy was achieved 
by altering the location of the miRNA within the expression cassette. 
Initial short-term experiments demonstrated that expressing the 
miRNAs from the 3′ end of the GFP gene rather than from the intron 
of the CB promoter lead to a 25% increase in the silencing capabilities 
of the miRNAs and also to a significant decrease in the variability of 
this effect. Furthermore, doubling the effective miRNA dose per vec-
tor by having the miRNAs expressed from both locations led to more 
rapid onset of Z-AAT knockdown (Figure 4a). Importantly, increase 
in miRNA production was seen for both the PolyA-3XmiR-CB-GFP 
and the Double-6XmiR-CB-GFP vectors as compared to the rAAV9-
intronCB-3xmiR-GFP vector. This seems to suggest that miRNA pro-
cessing from the intron of the CB promoter is not as efficient as from 
the 3′ end of the GFP gene. However, the long-term experiments 
that followed showed that the initial kinetic differences in knock-
down from the three vectors wanes overtime and by the 8 weeks 
the intronCB-3xmiR-GFP decreases in variability and augments in 
silencing efficacy. Western blot data from mice at day 90 analyzing 
the monomeric and polymeric Z-AAT fractions confirmed the effec-
tiveness of miRNA-mediated knockdown seen in serum Z-AAT but 
also revealed more variability in the decrease of monomeric Z-AAT 
in mice receiving the intronCB-3xmiR-GFP vectors as compared to 
PolyA-3XmiR-CB-GFP and the Double-6XmiR-CB-GFP vectors 
(Figure 4b,c). More importantly this data clearly establishes that 
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Figure 5 In vivo knockdown of Z-AAt with simultaneous augmentation of M-AAt after rAAV9 dual-function vector delivery. Transgenic mice 
expressing the human PiZ allele were injected with 1 × 1012 virus particles or rAAV9 expressing miRNAs against AAT and a de-targeted cMyc tagged wild-
type M-AAT cDNA under the control of the hybrid chicken β-actin promoter via the tail vein. (a) Serums from each cohort were collected on a weekly 
basis and were used to assess Z-AAT concentration by ELISA. Serum Z-AAT levels at each timepoint are expressed as a percent knockdown as compared 
to the rAAV9-GFP cohort by using a Z-specific AAT ELISA and M-AAT levels are calculated by using an ELISA to quantify the cMYC tag on the wild-type 
protein. Data are expressed as group means ±SEM (n = 6). Statistical significance was set at *≤0.05 as determined by a two-way ANOVA comparing each 
treatment group to the control rAAV-GFP group. Blue dashed line in the upper panel indicates therapeutic levels of wild-type PiM AAT as determined by 
the FDA and therapeutic knockdown of PiZ protein in the lower panel as determined by achieving levels expected in a PiZ heterozygous status. Total RNA 
from mouse livers was used to assay for the presence of the either (b) Z-AAT mRNA or (c) M-AAT mRNA by qRT-PCR. Data are expressed as group means 
±SEM (n = 6). *≤0.05 as determined by a two-way unpaired Student’s t-test. AAT, α-1 antitrypsin; ANOVA, analysis of variance; cDNA, complementary 
DNA; ELISA, enzyme-linked immunosorbent assay; CB-GFP, chicken β-actin–green fluorescent protein; FDA, Food and Drug Administration; mRNA, mes-
senger RNA; miRNA, microRNA; ND, not detected; qRT-PCR, quantitative reverse transcriptase-PCR; rAAV, recombinant adeno-associated virus.
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Z-AAT polymers are remarkably stable as there was no difference 
in the amount of Z-AAT polymers between GFP control mice and 
those receiving the anti-AAT miRNAs. Clearly, miRNAs would not 
be expected to decrease polymerized Z-AAT as they act on nascent 
Z-AAT mRNA; however, the remarkable stability of Z-AAT polymers 
throughout the 90-day study was surprising. The fact that there were 
no differences in the Z-AAT polymeric loads in the livers between 
groups of mice receiving GFP control vectors and anti-AAT miRNAs 
implies several things. First, this suggests that there was little new 
Z-AAT polymer formation during the 3-month study as one would 
expect that in the face of dramatic knockdown of newly synthesized 
Z-AAT as seen in the monomeric pool, few new polymeric aggre-
gates should arise during the experiment as compared to control mice 
where newly synthesized Z-AAT monomers are not limiting. Second, 
the results also imply that the turnover of hepatocytes with Z-AAT 
polymers is rather slow, again as no differences were seen between 
the control and treated mice after 3 months. If there should have been 
a significant amount of hepatocytes turnover it would been expected 
that treated mice would have smaller Z-AAT polymer pools in the 
liver since these would not be as easily replenished in the presence of 
a Z-AAT knockdown.
The potency and stability of the decrease in serum and liver 
Z-AAT observed in vivo suggests that either of these vectors would 
lower Z-AAT levels in Pi*ZZ patients to therapeutic levels, even 
below those seen in Pi*MZ heterozygote patients. However maximal 
clinical benefit would be derived from a concomitant rise in M-AAT 
circulation. For this reason we designed the dual-function vectors to 
also deliver a miRNA-resistant M-AAT complementary DNA. The in 
vivo studies with these dual-function vectors clearly demonstrate the 
feasibility of concomitant knockdown and augmentation of mutant 
and wild-type protein respectively. These experiments also revealed 
that the double configuration of miRNAs had a more rapid onset 
of Z-AAT knockdown but the overall efficacy over time was com-
parable to the PolyA-3XmiR-CB-AAT vector. More importantly, the 
improved knockdown kinetics of the Double-6XmiR-CB-AAT vec-
tor came at a cost as was seen from the decreased output in M-AAT 
(Figure 5a). Initially, it was hypothesized that this may have been a 
result of decreased M-AAT mRNA production due to the presence of 
miRNA within the intron of this construct, but as shown in Figure 5c, 
there was not statistically significant difference in M-AAT mRNA 
between the two groups. It is possible that while mRNA transcription 
and stability are not affected by the presence of miRNAs within the 
Figure 6 Artificial mirnA have minimal impact on endogenous mirnA liver profiles. Liver RNA was harvested 3 months post delivery from 
animals injected with the following vectors: intronCB-3xmiR-GFP, PolyA-3XmiR-GFP, Double-6XmiR-GFP, CB-GFP along with RNA from untreated PiZ 
mice and wild-type C57Bl6 mice was used to run a miRNA microarray. Each group consisted of five mouse RNA samples and was run independently 
with a single color (Cy5) microarray. CB, chicken β-actin; GFP, green fluorescent protein; miRNA, microRNA.
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intron, their translation into protein may be hindered as observed in 
the decrease circulating M-AAT levels in the serum of these mice.
If viral vector expressed miRNA-based therapy is to be trans-
lated into the clinic, one of the most pressing safety concerns is to 
determine what effect the expression of artificial miRNA has on 
endogenous miRNAs of the target organ? The question is a natu-
ral progression from the data that has been accumulating using 
first generation viral vector mediated RNAi. Emerging data from 
several labs using shRNA-mediated RNAi treatment for genetic 
disorders have reported severe adverse effects. An early land-
mark paper by Kay et al. described substantial hepatotoxicity and 
fatalities among mice receiving rAAV vector expressing shRNAs.12 
Similarly other early reports noted striatal neurotoxicity in mice 
treated with shRNA targeting the huntingtin gene and Purkinje cell 
loss in mice treated with shRNA against SCA1.13,14,19 More recently 
these initial findings have been corroborated in a mouse model 
of the dominantly inherited neurological disease DYT1 dystonia. 
This study demonstrated striatal atrophy associated with behav-
ioral dysfunction and death in mice receiving both therapeutic 
and control shRNA expressing rAAV vectors. Importantly the tox-
icity was encountered in wild-type and DYT1 mice.20 Collectively 
these studies convincingly suggest that vectors expressing high 
amounts shRNAs driven by strong pol-III promoters (e.g., U6 and 
H1) have the potential to be highly toxic. Initial evidence from 
two studies implicated the exogenous shRNA constructs could 
cause dysfunction of the endogenous miRNA pathway by over-
saturating key enzymes in the system.12,21 A recent study extending 
this mechanism revealed that least in part adverse effect associ-
ated with shRNA expression are due to the saturation of several 
rate-limiting components in the miRNA pathway. Specifically it 
was noted that shRNA saturated exportin-5 which is involved in 
the nuclear export or pre-miRNAs as well as all four human Ago 
proteins.22 Saturation of Ago proteins has serious implications 
since these proteins are involved in miRNA biogensis, oogen-
esis, embryogensis, and a myriad of other cellular pathways23–29 
To determine if our rAAV9 expressed anti-AAT miRNAs were 
disturbing the endogenous miRNA profiles of the liver, we inter-
rogated the livers of 30 mice with a miRNA microarray. Neither 
did the delivery of rAAV9-GFP or those expressing miRNAs have 
a significant impact on miRNA profiles. Notably mir-122 which 
is the most abundant miRNA produced in the liver and regulates 
fatty acid metabolism was unaffected in any group. While a few 
miRNAs were found to be statistically different among the groups, 
they were mostly confined to a twofold change with the exception 
of miR-1. In the array experiments comparing untreated mice, 
miR-1 was one of the miRNAs that was found to be upregulated 
in PiZ mouse livers when compared to wild-type mice. More 
importantly downregulation to near wild-type levels of miR-1 
was observed in all PiZ mice livers receiving rAAV9 (Figure 6a). 
Interestingly this correction of miR-1 levels was observed in the 
rAAV9-GFP group as well, suggesting that the downregualtion 
of miR-1 was not due to artificial miRNA expression by the vec-
tor but a consequence of rAAV9 transduction itself. While these 
results highlight the relatively unperturbed nature of miRNA pools 
in the liver after artificial miRNA delivery with rAAV9, it does 
not address whether endogenous miRNA function is affected. 
Recent studies by Khan et al. demonstrate that shRNA, miRNAs, 
and small interfering RNAs (siRNAs) transfection in vitro can all 
lead to altered gene regulation as RNA-induced silencing com-
plex or machinery downstream of exportin-5 is saturated.30 Their 
findings included the de-repression of miRNA-regulated genes as 
transfected small RNAs presumably competed with endogenous 
miRNAs for loading onto the RNA-induced silencing complex. 
These findings warrant further research using gene micorarrays 
to assess the consequences of rAAV delivered miRNAs on global 
gene profiles in vivo. Thus in summary, miRNA profiles seemed 
unperturbed and in some cases “corrected” back to wild-type lev-
els with rAAV9 delivery.
Considered more broadly, these findings raise the possibility 
that other diseases states requiring the combination of augmenta-
tion of a functional allele and suppression of a mutant allele might 
be addressed in a similar fashion. Disorders such as amyotrophic 
lateral sclerosis, Huntington disease cerebral ataxia, and optic atro-
phies, in which mutant alleles cause a severe autosomal dominant 
disease, but in which an allele-specific knockdown might only be 
feasible if the functional allele were modified to convey resistance to 
a miRNA-based knockdown. It is also significant that our manipu-
lations result in minimal perturbations of endogenous miRNA 
profiles. This is potentially important for considering the safety of 
single agent miRNA-based approaches, which would have an even 
broader scope of uses, such as antiviral therapy directed against 
hepatitis B virus or hepatitis C virus. As with the genetic diseases 
considered above, these are conditions in which the downregula-
tion of target genes is likely to be necessary for prolonged periods 
table 2 statistically significant changes in liver mirnA profiles
Group 1 Group 2
B6-mock control PiZ-mock control
reporter name P value
Mean intensity  
(n = 5)
Mean intensity 
(n = 5)
log2 
(G2/G1)
mmu-miR-762 2.39E-02 525 1,099 1.07
mmu-miR-23a 4.03E-02 1,247 1,593 0.35
mmu-miR-1 4.95E-02 126 2,776 4.46
mmu-miR-341a 4.97E-02 4,340 2,287 −0.92
PiZ-cB-GFP PiZ-mock control
mmu-miR-1 6.03E-03 5 2,776 9.13
mmu-miR-148a 7.48E-03 1,841 1,058 −0.80
mmu-miR-720 9.33E-03 1,264 3,440 1.44
mmu-miR-30c 1.03E-02 2,830 1,757 −0.69
mmu-miR-146a 1.71E-02 362 175 −1.05
mmu-miR-30d 4.64E-02 627 454 −0.47
PiZ-PolyA 3Xmir PiZ-mock control
mmu-miR-2145 1.40E-02 573 114 −2.32
mmu-miR-1 2.28E-02 22 2,776 6.95
mmu-miR-690 2.41E-02 3,071 534 −2.52
mmu-miR-720 4.31E-02 1,816 3,440 0.92
PiZ-double 6Xmir PiZ-mock control
mmu-miR-146a 1.53E-02 445 175 −1.35
mmu-miR-1 3.04E-02 115 2,776 4.59
aSignificant values are listed in the P value column.
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of time. Therefore, emergence of the rAAV-based miRNA platform 
as a means to address these problems could hold great promise in 
this setting as well. There are potential limitations of rAAV-based 
delivery, as the potential consequence of immune-mediated dele-
tion of transduced cells by anti-AAV capsid T cells continues to be 
an unresolved question. In addition as was evident from the sta-
bility and permanence of the Z-AAT polymeric pool in the liver 
of treated mice, intervention at an early stage in the disease may 
be necessary to prevent liver damage and disease progression. 
Nonetheless, this approach clearly warrants further study and may 
lead to clinical translation for a number of unmet medical needs.
MAterIAls And Methods
rAAV9 packaging and purification. Recombinant AAV9 vectors used in 
this study were generated, purified, and titered by the UMass Gene Therapy 
Vector Core as previously described.31 To clone in the miRNAs a 425 bp 
sequence containing all three miRNAs in tandem was cloned into CB intron 
by replacing 315 bp intron sequence between enzyme sites SgrAI and XbaI. 
Cloning of the miRNAs at the polyA region was accomplished by inserting 
the 425 bp fragment at the NotI site 5 bp upstream of the polyA region.
Cell culture and transfection. HEK-293 cells were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum 
and 100 mg/l of penicillin-streptomycin (Gemini Bio-products, West 
Sacramento, CA). Cells were maintained in a humidified incubator at 37 °C 
and 5% CO2. Plasmids were transiently transfected using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions. Cell culture supernatants were collected at 24, 48, and 72 hours, and 
cell lysates were collected at 72 hours.
Serum AAT ELISAs. Human AAT ELISA: Total AAT protein was detected 
by ELISA. High binding extra, 96-well plate (Immulon 4; Dynatech 
Laboratories, Chantilly, VA) were coated with 100 µl of human specific goat 
anti-AAT (1:500 diluted; Biomedicals, Solon, OH) in Voller’s buffer over-
night at 4 °C. After blocking with 1% non-fat dry milk in phosphate-buff-
ered saline with Tween 20, duplicate standard curves (Athens Research and 
Technology, Athens, GA) and serially diluted unknown samples were incu-
bated in the plate at room temperature for 1 hour, a second antibody, goat 
anti-hAAT(HRP) (1:5,000 diluted; Abcam, Cambridge, MA) was incubated 
at room temperature for 1 hour. The plate was washed with phosphate-buff-
ered saline-Tween 20 between reactions. After reaction with TMB peroxi-
dase substrate (KPL, Gaithersburg, MD) reactions were stopped by adding 
2 N H2SO4 (Fisher Scientific, Hudson, NH). Plates were read at 450 nm on a 
VersaMax microplate reader (Molecular Devices, Sunnyvale, CA).
Z-AAT ELISA: Human Z-AAT protein levels were detected by ELISA 
with coating antibody specific for human Z-AAT (1:100 diluted mouse-
anti-human α-1-antitrypsin-Z; Cell Sciences, Fair Lawn, NJ). Standard 
curves were created with PiZ mouse serum with 5% bovine serum 
albumin (Sigma, St Louis, MO). Serially diluted unknown samples were 
incubated in the plate at 37 °C for 1 hour. The secondary antibody and the 
next step were same as the standard human-AAT ELISA described above, 
except the secondary antibody was diluted in 5% bovine serum albumin 
and incubated in the plate at 37 °C for 1 hour.
c-Myc ELISA: c-Myc tag levels were quantified by a method similar to 
that described above. Plates were coated with a c-Myc antibody (1:1,000 
diluted Goat anti-c-Myc; Abcam), plates were then blocked with 5% 
bovine serum albumin at 37 °C for 1 hour. To create the standard curve 
C57Bl/6 mice were dosed via tail vein with c-Myc-AAT expressing vector, 
at 2 weeks serum were collected and pooled. The amount c-Myc-AAT 
in the serums was then quantified with the human specific AAT ELISA 
described above. The obtained values were then used to produce a 
standard of c-Myc protein for the c-Myc ELISA.
real-time rt-Pcr
RNA extraction: Flash frozen mouse liver tissue was ground in a pestle 
and mortar and used to extract either small or total RNA using the 
mirVana miRNA RNA Isolation Kit (Ambion, Austin, TX) according to 
the manufacturer’s instructions.
microRNA qRT-PCR: mircoRNA was primed and reverse-transcribed 
with TagMan MicroRNA reverse transcription Kit (Applied Biosystems, 
Foster City, CA). Quantitative PCR was performed in duplicate with gene-
specific RT-miRNA primers, and PCR assays were as designed by Applied 
Biosystems, using TaqMan Gene Expression Master mix (Applied Biosystems) 
in a StepOne Plus real-time PCR instrument (Applied Biosystems).
PiM and PiZ qRT-PCR: Total RNA was primed with oligo(dT) and 
reverse-transcribed with SuperScript III First-Strand Synthesis kit for 
RT-PCR (Invitrogen). Quantitative PCR were performed by gene-specific primer 
pairs. PiM and PiZ share the primers but differ in the probes. Forward 
primer CCAAGGCCGTGCATAAGG, reverse primer: GGCCCCAGCAGC 
TTCAGT, PiZ probe: 6FAM-CTGACCATCGACAAGA-MGBNFQ, and 
PiM probe: 6FAM-CTGACCATCGACGAGA-MGBNFQ. Reactions were 
performed using TaqMan Gene Expression Master mix (Applied Biosystems) 
in a StepOne Plus real-time PCR instrument (Applied Biosystems).
Z-AAT transgenic mice and rAAV9 delivery. The PiZ-transgenic mice 
used in this study have been described.11 All animal procedures were per-
formed according to the guidelines of the Institutional Animal Care and Use 
Committee of the University of Massachusetts Medical School. rAAV9 vector 
was administered by mouse tail vein injection in a volume of 200 μl with titer 
of 1 × 1012 vps. The injections were performed in the most accessible vessels 
veins that run the length of both lateral aspects of the tail by grasping the tail 
at the distal end. Blood was collected through the facial vein pre-injection and 
every week after tail vein rAAV9 delivery until termination of the studies.
Liver histology. For determination of histological changes, liver samples 
were fixed in 10% neutral-buffered formalin (Fisher Scientific), and 
embedded in paraffin. Sections (5 µm) were stained with hematoxylin and 
eosin and PAS with or without diastase digestion.
Immunohistochemistry for hAAT, was performed as described,13 
briefly tissue sections (5 µm) were deparaffinized, rehydrated, and blocked 
for endogenous peroxidase with 3% hydrogen peroxide in methanol for 
10 minutes. To detect hAAT expression, tissue sections were incubated 
with primary antibody, rabbit antihuman AAT (1:800; RDI/Fitzgerald 
Industries, Acton, MA), for overnight at 4 °C. Staining was detected using 
ABC-Rb-HRP and DAB kits (Vector Laboratories, Burlingame, CA).
Histology image analysis. Slides were stained for PASD to remove glyco-
gen. Whole digital slide images were created using an Aperio CS ScanScope 
(V, CA) and analyzed using the positive pixel count algorithm (version 9). 
PASD-positive globules were expressed as the proportion of strong positive 
pixels to total pixels using a hue value of 0.9, hue width of 0.15, and color 
saturation threshold of 0.25. The intensity threshold for strong positivity 
was set to an upper limit of 100.
Analysis of Z-AAT protein monomer and polymer. For soluble/insoluble pro-
tein separation, 10 mg of whole liver was added to 2 ml buffer at 4 °C (50 mmol/l 
Tris-HCl (pH 8.0), 150 mmol/l NaCl, 5 mmol/l KCl, 5 mmol/l MgCl2, 0.5% 
Triton X-100, and 80 μl of complete protease inhibitor stock). The tissue was 
homogenized in a prechilled Dounce homogenizer for 30 repetitions, then 
vortexed vigorously. A 1-ml aliquot was passed through a 28-gauge needle 
10 times. The total protein concentration of the sample was determined, and 
a 5-μg total liver protein sample was aliquoted and centrifuged at 10,000g for 
30 minutes at 4 °C. Supernatant (soluble (S) fraction) was immediately 
removed into fresh tubes; extreme care was taken to avoid disturbing the 
pellet (insoluble (I) fraction). The insoluble polymers pellet (I fraction) was 
denatured and solubilized via addition of 10 l chilled cell lysis buffer (1% 
Triton X-100, 0.05% deoxycholate, 10 mmol/l EDTA in phosphate-buffered 
saline), vortexed for 30 seconds, sonicated on ice for 10 minutes and vortexed. 
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To each soluble and insoluble sample, 2.5 sample buffer (50% 5 sample buf-
fer (5% sodium dodecyl sulfate, 50% glycerol, 0.5 mol/l Tris (pH 6.8)), 10% 
mercaptoethanol, 40% ddH2O) was added at a volume of 50% of the sample 
volume. Samples were boiled and loaded for sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE); equal amounts of total liver 
protein were loaded per soluble–insoluble pair in quantitative experiments. 
Densitometry was performed using Image J Software (NIH, Bethesda, MD).
Serum chemistry. All serum samples were analyzed by UMass Mouse 
Phenotyping Center Analytical Core, using the NExCT Clinical Chemistry 
Analyzer (Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ). 
Serum was analyzed for alanine aminotransferase and aspartate amin-
otransferase according the manufacturers specifications.
miRNA microarray expression analysis. We isolated 8 μg of total RNA 
from flash frozen mouse livers using the mirVana miRNA isolation kit 
(Ambion). The experimental design included six groups with RNA sam-
ples from five mice each which were assayed on single color arrays for a 
total of 30 independent microarrays. In brief, the RNA was labeled with 
Cy5 and hybridized to dual-channel microarray μParaFlo microfluidics 
chips (LC Sciences, Houston, TX) containing miRNA probes to mouse 
mature miRNAs available in the Sanger miRBase database (Release 16.0) as 
described.32 Each of the spotted detection probes consisted of a nucleotide 
sequence complementary to a specific miRNA sequence and a long non-
nucleotide spacer that extended the specific sequence away from the chip 
surface. Fluorescence images were collected with a laser scanner (GenePix 
4000B; Molecular Devices) and digitized using Array-Pro image analysis 
software (Media Cybernetics, Bethesda, MD). The data were analyzed, 
including background subtraction, with a LOWESS (locally weighted 
regression) method on the background-subtracted data as described.33 
The normalization is to remove system related variations, such as sample 
amount variations and signal gain differences of scanners. Samples were 
considered positive only if transcripts had a signal intensity higher than 3 
times (background-subtracted data) and the spot coefficient of variation 
<0.5. Coefficient of variation as calculated by (subtracted data)/(signal 
intensity), and in which repeating probes on the array produced signals 
from at least 50% of the repeating probes above detection level. Data are 
represented as a Log2 transformation. The data were further filtered to 
remove miRNAs with (normalized) intensity values below a threshold 
value of 32 across all samples. t-test were performed between “control” and 
“test” sample groups where T values are calculated for each miRNA, and 
P values are computed from the theoretical t-distribution. If P ≤ 0.05, it is 
plotted as red spot in a log scatter plot.
suPPleMentArY MAterIAl
Figure S1. Long-term in vivo silencing of human AAT by rAAV9 
expressed miRNAs.
Figure S2. Liver function in response to rAAV9 delivery.
Figure S3. In vitro assessment of dual-function pro-viral plasmid.
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